drugset / Trial / NCT05274204
Individual Patient Expanded Access to CA102N
Summary
This study is an individual patient expanded access protocol that the subject enrolled had completed the combination treatment of CA102N plus Lonsurf for at least 12 cycles.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CA102N | Other / unclassified | 0.72 mg/kg | — |